advertisement
Abstract #91533 Published in IGR 21-4
Visual field progression in patients with severe glaucoma
Maul EJ; Kastner A; Schmidt J; Tapia JA; Morales C; Maul EAGraefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1579-1586
PURPOSE: To assess the cumulative risk of progression in glaucomatous eyes in the severe stage of disease. METHODS: This was a retrospective observational study. Patients that had severe damage in at least one eye, as defined by three criteria including a mean deviation of ≤ - 20 dB, were included. Glaucoma progression was defined as a loss of ≥ 2 dB in mean deviation confirmed in three consecutive visual field tests, or a persistent loss of two or more lines of vision-not attributable to non-glaucomatous causes-in three consecutive follow-up examinations. Kaplan-Meier survival analysis was used to assess the cumulative incidence of progression of the first eye to reach endpoint in cases where both eyes were eligible. RESULTS: A total of 143 eyes from 119 patients, were studied over a mean period of 4.9 ± 2.9 years. Baseline mean deviation was - 25.3 ± 3.6 dB. Twenty-three eyes of 22 patients reached the progression endpoint: 14 eyes by visual field criteria and 9 by visual acuity criteria. The cumulative 5-year risk of progression estimated by Kaplan-Meier analysis was 14.6% (95% confidence interval: 6.1-22.2%). CONCLUSIONS: In severe glaucoma patients, we found a cumulative incidence of progression of 2.9% per year during the first 5 years of follow-up. Similar incidences have been reported in other studies of glaucoma at different stages of severity.
Department of Ophthalmology, School of Medicine, Pontificia Universidad Católica de Chile, Ave. Apoquindo 3990 Suite 708, PC:7550112, Santiago, Chile. emauld@gmail.com.
Full articleClassification:
6.20 Progression (Part of: 6 Clinical examination methods)
